ORLANDO HEALTH
- Type
- Teaching hospital
- Where
- Orlando, FL
- Medicare CCN
- 100006
- Received
- $3,986,437 in 436 records, 2020 ($296,781 general, $3,689,655 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Orlando Health, Inc. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, LLC Fuzzy (name and state)
- Nonprofit contractor: Orlando Health Inc Fuzzy (name and state)
- Plan sponsor: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Federal award recipient: ORLANDO HEALTH, INC Fuzzy (name and state)
- Federal award recipient: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying registrant: ORLANDO HEALTH Fuzzy (name and state)
- Nonprofit: ORLANDO HEALTH INC Fuzzy (name and state)
- Patent assignee: Orlando Health, Inc. Fuzzy (name and state)
- Trademark owner: Orlando Health, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 43 | $296,781 |
| 2020 | Research payment | 393 | $3,689,655 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 393 | $3,689,655 |
| Grant | 12 | $146,959 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 13 | $69,931 |
| Education | 5 | $46,947 |
| Royalty or License | 1 | $18,262 |
| Space rental or facility fees (teaching hospital only) | 6 | $6,600 |
| Gift | 3 | $5,623 |
| Consulting Fee | 2 | $2,000 |
| Charitable Contribution | 1 | $456 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,758 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Germl | 2020 |
| 2020-12-31 | Edwards Lifesciences Corporation | $922 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2020 | |
| 2020-12-31 | Edwards Lifesciences Corporation | $608 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $547 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $456 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Masimo Corporation | $144 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-24 | Amgen Inc. | $3,427 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | T-VEC + Pembrolizumab in patients progressing on prior anti-PD-1 therapy | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $4,750 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $64,800 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A MULTICENTER PHASE 2, OPEN-LABEL TRIAL OF INTRATUMORAL PIL-12 PLUS ELECTROPORATION IN COMBINATION WITH INTRAVENOUS PEMB | 2020 |
| 2020-12-17 | ABBVIE INC. | $213 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-12-16 | Alexion Pharmaceuticals, Inc. | $4,000 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-12-16 | Celgene Corporation | $2,250 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-12-15 | Celgene Corporation | $1,550 | Research payment | Cash or cash equivalent | PhIII QUAZAR Lower Risk MDS (AZA-MDS-003) | 2020 | |
| 2020-12-14 | ABBVIE INC. | $1,000 | Research payment | Cash or cash equivalent | M14-011 | 2020 | |
| 2020-12-11 | Aesculap Implant Systems, LLC | $4,620 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | PFIZER INC. | $74,984 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $811 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $192 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Alexion Pharmaceuticals, Inc. | $180 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $353 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $353 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $304 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $304 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $304 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $304 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $257 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $257 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $257 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $257 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $257 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $257 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $61 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $61 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $61 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $61 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $61 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $61 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $61 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $49 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $49 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-02 | QOL Medical, LLC | $44,504 | Research payment | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | A Study of the Association of Genetic Sucrase-Isomaltase Deficiency (GSID) Allele Frequencies from Formalin Fixed Paraff | 2020 |
| 2020-12-02 | ABBVIE INC. | $21 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-11-27 | C. R. Bard, Inc. & Subsidiaries | $1,000 | Research payment | Cash or cash equivalent | LUTONIX Device, BD Interventional - Peripheral Intervention | SAFE-DCB Registry BPV14006 | 2020 |
| 2020-11-24 | Novocure Inc. | $2,000 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2020 |
| 2020-11-21 | Amgen Inc. | $8,375 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) | 2020 |
| 2020-11-20 | Genentech, Inc. | $749 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-11-19 | Clovis Oncology, Inc. | $7,956 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-11-19 | Pharmacyclics LLC, an AbbVie Company | $2,555 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-11-19 | Pharmacyclics LLC, an AbbVie Company | $2,555 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-11-19 | Pharmacyclics LLC, an AbbVie Company | $1,103 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-11-19 | Zimmer Biomet Holdings, Inc. | $79 | Grant | Cash or cash equivalent | Spine-None Device, Spine | 2020 | |
| 2020-11-19 | Clovis Oncology, Inc. | $72 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-11-18 | Alexion Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | PNH Registry | 2020 | |
| 2020-11-18 | Genentech, Inc. | $79 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-11-16 | Genentech, Inc. | $13,981 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IPATASERTIB IN COMBINATION WITH PACLITAXEL IN TNBC AND HR BREAST CANCER | 2020 |
| 2020-11-16 | Covidien LP | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-16 | Covidien LP | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-16 | Immunomedics, Inc. | $5,084 | Research payment | Cash or cash equivalent | Trodelvy Drug, Oncology | IMMU-132-09 | 2020 |
| 2020-11-10 | Pharmacyclics LLC, an AbbVie Company | $500 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-11-06 | Medical Device Business Services, Inc. | $13,429 | Grant | Cash or cash equivalent | ANSPACH Device, Power Tools | 2020 | |
| 2020-11-06 | Genentech, Inc. | $1,746 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2020 |
| 2020-11-06 | Medical Device Business Services, Inc. | $1,577 | Grant | Cash or cash equivalent | Anspach Helix Device, Power Tools | 2020 | |
| 2020-11-05 | Medtronic USA, Inc. | $350 | Research payment | Cash or cash equivalent | INFUSE Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2020 |
| 2020-11-04 | Abbott Laboratories | $2,285 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-11-04 | ABBVIE INC. | $1,250 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-11-03 | Pharmacyclics LLC, an AbbVie Company | $2,555 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-11-03 | Pharmacyclics LLC, an AbbVie Company | $2,555 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-11-03 | Pharmacyclics LLC, an AbbVie Company | $1,103 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-11-02 | Pulmonx Corporation | $1,350 | Research payment | Cash or cash equivalent | Pulmonx Endobronchial Valve EBV Device, Pulmonology | Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment | 2020 |
| 2020-10-30 | VIEWRAY TECHNOLOGIES INC | $2,500 | Research payment | Cash or cash equivalent | MRIdian Device, RADIOTHERAPY | Prospective Phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borde | 2020 |
| 2020-10-28 | PFIZER INC. | $6,600 | Research payment | Cash or cash equivalent | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PART | 2020 |
| 2020-10-28 | Abbott Laboratories | $450 | Research payment | Cash or cash equivalent | Nanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2020 |
| 2020-10-26 | Immunomedics, Inc. | $5,398 | Research payment | Cash or cash equivalent | Trodelvy Drug, Oncology | IMMU-132-09 | 2020 |
| 2020-10-26 | Genentech, Inc. | $1,410 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2020 |
| 2020-10-26 | Janssen Research & Development, LLC | $538 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2020 | |
| 2020-10-23 | Novocure Inc. | $3,000 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-10-23 | Novocure Inc. | $30 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2020 |
| 2020-10-22 | Clovis Oncology, Inc. | $3,268 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-10-21 | QOL Medical, LLC | $4,417 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | 2020 | |
| 2020-10-21 | Abbott Laboratories | $327 | Research payment | Cash or cash equivalent | Amplatzer Duct Occluder II Device, Vascular | AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) Clinical Study | 2020 |
| 2020-10-21 | Masimo Corporation | $65 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-10-19 | ABBVIE INC. | $5,685 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-10-19 | Alnylam Pharmaceuticals Inc. | $4,450 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2020 |
| 2020-10-19 | Alnylam Pharmaceuticals Inc. | $4,000 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2020 |
| 2020-10-16 | VIEWRAY TECHNOLOGIES INC | $6,000 | Research payment | Cash or cash equivalent | MRIdian Device, RADIOTHERAPY | Prospective Phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borde | 2020 |
| 2020-10-16 | VIEWRAY TECHNOLOGIES INC | $2,000 | Research payment | Cash or cash equivalent | MRIdian Device, RADIOTHERAPY | Prospective Phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borde | 2020 |
| 2020-10-15 | PFIZER INC. | $859 | Research payment | Cash or cash equivalent | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PART | 2020 |
| 2020-10-14 | Alexion Pharmaceuticals, Inc. | $5,000 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-10-13 | Clovis Oncology, Inc. | $1,311 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-10-07 | PFIZER INC. | $3,250 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2020 | |
| 2020-10-07 | Medtronic USA, Inc. | $195 | Research payment | Cash or cash equivalent | INFUSE Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2020 |
| 2020-10-07 | Medtronic USA, Inc. | $130 | Research payment | Cash or cash equivalent | INFUSE Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2020 |
| 2020-10-02 | Janssen Research & Development, LLC | $1,440 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2020 | |
| 2020-09-30 | Abbott Laboratories | $80 | Research payment | In-kind items and services | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2020 |
| 2020-09-28 | ABBVIE INC. | $3,199 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-09-24 | Genentech, Inc. | $35,328 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | 2020 |
| 2020-09-24 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IPATASERTIB IN COMBINATION WITH PACLITAXEL IN TNBC AND HR BREAST CANCER | 2020 |
| 2020-09-23 | QOL Medical, LLC | $4,185 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | 2020 | |
| 2020-09-22 | F. Hoffmann-La Roche AG | $8,437 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2020 |
| 2020-09-22 | PFIZER INC. | $7,500 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY | 2020 |
| 2020-09-22 | Novartis Pharmaceuticals Corporation | $7,055 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN | 2020 |
| 2020-09-22 | Pharmacyclics LLC, an AbbVie Company | $4,250 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-09-22 | Pharmacyclics LLC, an AbbVie Company | $1,103 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-09-21 | Janssen Research & Development, LLC | $3,250 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2020 | |
| 2020-09-21 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | INGENIO Device, BRADY | SAMURAI | 2020 |
| 2020-09-18 | Merck Sharp & Dohme LLC | $2,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-09-17 | Clovis Oncology, Inc. | $3,268 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-09-17 | Takeda Pharmaceuticals U.S.A., Inc. | $672 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2020 | |
| 2020-09-16 | Genentech, Inc. | $1,499 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-09-14 | E.R. Squibb & Sons, L.L.C. | $2,070 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Melanoma 2 3L IPI Progressors | 2020 |
| 2020-09-11 | Boston Scientific Corporation | $1,619 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2020 |
| 2020-09-09 | Novocure Inc. | $8,000 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2020 |
| 2020-09-07 | Janssen Research & Development, LLC | $1,124 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2020 | |
| 2020-09-02 | QOL Medical, LLC | $2,557 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | 2020 | |
| 2020-09-02 | E.R. Squibb & Sons, L.L.C. | $900 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study | 2020 |
| 2020-09-01 | Genentech, Inc. | $1,900 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2020 |
| 2020-08-31 | Janssen Research & Development, LLC | $3,414 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2020 | |
| 2020-08-27 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2020 |
| 2020-08-27 | ABBVIE INC. | $1,512 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-08-21 | GENZYME CORPORATION | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | THYMOGLOBULIN Biological, Oncology | 2020 | |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $4,147 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $2,555 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $2,375 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $1,103 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $1,103 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $1,103 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $1,000 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $508 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $410 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $381 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-08-18 | Genentech, Inc. | $13,282 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IPATASERTIB IN COMBINATION WITH PACLITAXEL IN TNBC AND HR BREAST CANCER | 2020 |
| 2020-08-17 | Merck Sharp & Dohme LLC | $10,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-08-17 | AstraZeneca UK Limited | $3,104 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as | 2020 |
| 2020-08-07 | Merck Sharp & Dohme LLC | $64,800 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A MULTICENTER PHASE 2, OPEN-LABEL TRIAL OF INTRATUMORAL PIL-12 PLUS ELECTROPORATION IN COMBINATION WITH INTRAVENOUS PEMB | 2020 |
| 2020-08-06 | Clovis Oncology, Inc. | $8,028 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-08-06 | Clovis Oncology, Inc. | $55 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2020 |
| 2020-08-05 | QOL Medical, LLC | $1,627 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | 2020 | |
| 2020-08-05 | Abbott Laboratories | $956 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-08-04 | Alexion Pharmaceuticals, Inc. | $4,500 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic An | 2020 | |
| 2020-08-04 | Celgene Corporation | $1,400 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conve | 2020 | |
| 2020-07-30 | Janssen Research & Development, LLC | $3,222 | Research payment | Cash or cash equivalent | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment | 2020 | |
| 2020-07-29 | ABBVIE INC. | $1,779 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-07-28 | Clovis Oncology, Inc. | $3,607 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-07-28 | Merck Sharp & Dohme LLC | $805 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-07-21 | Bard Access Systems, Inc. | $30,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-07-16 | Takeda Pharmaceuticals U.S.A., Inc. | $232 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2020 | |
| 2020-07-15 | Varian Medical Systems, Inc. | $20,000 | Research payment | Cash or cash equivalent | Halcyon Device, Devices | Palliative Radiation Therapy - Orlando Health | 2020 |
| 2020-07-15 | Medtronic USA, Inc. | $4,000 | Research payment | Cash or cash equivalent | INFUSE Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2020 |
| 2020-07-15 | Varian Medical Systems, Inc. | $200 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-14 | BIOTRONIK INC. | $304 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-07-14 | BIOTRONIK INC. | $304 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-07-14 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-07-14 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 |
The latest 200 records of 436.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Orlando, FL, county Orange County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Orlando, FL | County Orange County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 319,758 | 1,471,937 | 22,416,077 |
| Population, 2020 census P1 | 307,573 | 1,429,908 | 21,538,187 |
| Median age B01002 | 35.1 | 36.6 | 42.6 |
| Under 18 B01001 | 21.4% | 21.4% | 19.5% |
| 65 and over B01001 | 11.3% | 13.0% | 21.3% |
| Households B11001 | 131,179 | 527,776 | 8,752,810 |
| Foreign born B05002 | 25.4% | 24.3% | 21.9% |
| Median household income B19013 | $72,336 | $79,719 | $74,568 |
| Median family income B19113 | $81,945 | $92,968 | $89,891 |
| Per capita income B19301 | $43,312 | $41,160 | $42,609 |
| Poverty rate B17001 | 14.7% | 13.0% | 12.6% |
| Unemployment rate B23025 | 5.2% | 5.5% | 4.8% |
| Civilian labor force B23025 | 186,466 | 803,825 | 11,016,578 |
| Mean commute (minutes) B08013 | 26.2 | 28.0 | 28.0 |
| Bachelor's degree or higher B15003 | 42.5% | 39.3% | 34.1% |
| Housing units B25001 | 148,754 | 586,805 | 10,256,470 |
| Owner-occupied B25003 | 39.5% | 56.8% | 67.6% |
| Renters B25003 | 60.5% | 43.2% | 32.4% |
| Median home value B25077 | $394,100 | $390,100 | $359,000 |
| Median gross rent B25064 | $1,747 | $1,775 | $1,669 |
| White, not Hispanic B03002 | 31.2% | 35.9% | 50.4% |
| Black B03002 | 22.2% | 19.1% | 14.6% |
| Hispanic or Latino B03002 | 35.4% | 33.8% | 27.4% |
| Asian B03002 | 4.8% | 5.3% | 2.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Orlando, FL.
Comments